Month: August 2025

NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) — Enigmatig Limited (NYSE American: EGG) (“Enigmatig” or the “Company”), a global business enabler empowering small and medium-sized enterprises (SMEs) to scale across borders, today rang the Closing Bell at the New York Stock Exchange (“NYSE”) to mark its recent listing and reaffirm its mission to power the global ambitions of bold, forward-thinking businesses.Enigmatig Founder and CEO Desmond Foo and Team, on NYSE American Podium for Closing Bell Enigmatig began trading on June 18, 2025, following the completion of its initial public offering of 3,005,200 Class A ordinary shares at US$5.00 per share including the partial exercise of the underwriters’ overallotment option. The offering raised gross proceeds of approximately US$15 million. Prime Number Capital LLC acted as the sole book-running...

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity. The accelerated approval is based on part 1 of the ESSENCE trial, in which Wegovy® demonstrated a statistically significant and superior improvement in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis compared to placebo. The clinical data from ESSENCE showed that at week 72,...

FUKUOKA, Japan, Aug. 15, 2025 (GLOBE NEWSWIRE) — rYojbaba Co., Ltd. (Nasdaq: RYOJ) (“rYojbaba” or the “Company”), a Japanese labor consulting and health services company, today announced the closing of its initial public offering of 1,250,000 Japanese common shares at a public offering price of US$4.00 per share. The total gross proceeds from the offering, before deducting underwriting discounts and other offering expenses payable by rYojbaba, was US$5 million. rYojbaba’s Japanese common shares began trading on the Nasdaq Capital Market on August 14, 2025, under the ticker symbol “RYOJ”. In addition, rYojbaba has granted the underwriters a 45-day option to purchase up to an additional 187,500 Common Shares at the public offering price per share, less the underwriting discount, to cover over-allotments, if any. rYojbaba intends...

    – Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial – Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP® companion diagnostic – Secured new service contract with EU biotech for Allarity Medical LaboratoryTARPON SPRINGS, Fla., August 15, 2025 — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the second quarter ended June 30, 2025. “The second quarter of 2025 marked a period of strong operational execution for Allarity. Most notably, we continued to advance our lead program, stenoparib, with strong...